Embark Early Education Ltd
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 5.1K
- Market Cap
- $1.3B
- Website
- http://evotec.com
- Introduction
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
Halozyme proposes to acquire Evotec for €11.00 per share, creating a leading global pharma services company with capabilities in drug discovery, biologic manufacturing, and drug delivery technologies, diversifying and scaling Halozyme's revenue and EBITDA into the next decade. The all-cash transaction would be funded by cash on hand and new debt, with expected net leverage less than 2x two years post-close.
Halozyme Makes Unsolicited €2B Takeover Bid for Drug R&D Services Firm Evotec
Halozyme proposes €2 billion acquisition of Evotec, offering €11.00 per share in cash, a 109% premium to Evotec's Oct. 15 stock price. Evotec, with 4,000 employees, faces recent setbacks including a cyberattack and restructuring. Halozyme, with 373 employees, offers Enhanze drug delivery tech used by Roche, Takeda, Eli Lilly, Pfizer, and AbbVie.
Halozyme bids for Evotec; BeiGene gets a new name
Halozyme offers to buy Evotec for €2B; Bluebird records first revenue from Lyfgenia; BeiGene rebrands as BeOne Medicines; Adaptimmune to lay off 33% of staff; Leerink Partners adds senior M&A directors; Abeona awaits FDA decision on pz-cel.
Evotec SE reports 9M 2024 results: Strategic Progress and Successful Expansion Amid
Evotec SE reports Q3 2024 financial results, highlighting strategic progress despite challenging market conditions. Just - Evotec Biologics shows robust growth, and new partnerships with Pfizer, BMS, and Novo Nordisk are established. The Priority Reset initiative aims for over €40m annualised adjusted EBITDA improvement. A new biologics facility in Toulouse, France, is opened, and full-year 2024 guidance is confirmed.
Corporate Presentation November 2024
Kazia Therapeutics' November 2024 corporate presentation highlights its late-clinical-stage oncology drug development, focusing on high-quality, differentiated clinical-stage assets. Key assets include the brain-penetrant PI3K/mTOR inhibitor Paxalisib, in trials for various brain cancers, and the selective VEGFR3 inhibitor EVT801, targeting lymphangiogenesis in advanced solid tumors. The company's licensing-driven model and potential non-dilutive income opportunities are also discussed.
TVM TO HOST THOUGHT-PROVOKING SESSIONS AT BIO-EUROPE 2024
TVM Capital Life Science hosts AI-focused sessions at BIO-Europe 2024, discussing AI's impact on biopharma, drug discovery, and diagnostics.
Quantro Therapeutics - Products, Competitors, Financials, Employees
QUANTRO Therapeutics and IMP collaborate to advance transcriptomic drug discovery, focusing on transcription factor complexes for cancer therapy. The partnership integrates genetic screening to understand transcription factor interactions, aiming to develop treatments for untreatable diseases.
QUANTRO Therapeutics and IMP enter into research collaboration to advance transcriptomic drug discovery
QUANTRO Therapeutics and IMP collaborate to advance transcriptomic drug discovery, focusing on transcription factor complexes for cancer therapy. The partnership leverages QUANTRO's transcriptomic discovery platform and IMP's genetic screening technologies to identify and characterize key co-factors and regulators, aiming to accelerate drug discovery for untreatable diseases.
QUANTRO Therapeutics and IMP enter into research collaboration to advance transcriptomic drug discovery for cancer therapy
QUANTRO Therapeutics collaborates with IMP to advance transcriptomic drug discovery, focusing on transcription factor complexes for cancer therapy. The partnership leverages QUANTRO's transcriptomic discovery platform and IMP's genetic screening to target previously 'undruggable' transcription factors, aiming to accelerate drug discovery for untreatable diseases.
© Copyright 2025. All Rights Reserved by MedPath